RU2006123312A - Фармацевтические композиции - Google Patents
Фармацевтические композиции Download PDFInfo
- Publication number
- RU2006123312A RU2006123312A RU2006123312/15A RU2006123312A RU2006123312A RU 2006123312 A RU2006123312 A RU 2006123312A RU 2006123312/15 A RU2006123312/15 A RU 2006123312/15A RU 2006123312 A RU2006123312 A RU 2006123312A RU 2006123312 A RU2006123312 A RU 2006123312A
- Authority
- RU
- Russia
- Prior art keywords
- arthritis
- rheumatoid arthritis
- mtor inhibitor
- medicament
- activity against
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 10
- 206010003246 arthritis Diseases 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 229940124302 mTOR inhibitor Drugs 0.000 claims 8
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000002950 fibroblast Anatomy 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 241001111421 Pannus Species 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0327840.5A GB0327840D0 (en) | 2003-12-01 | 2003-12-01 | Organic compounds |
| GB0327840.5 | 2003-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006123312A true RU2006123312A (ru) | 2008-01-20 |
Family
ID=29798110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006123312/15A RU2006123312A (ru) | 2003-12-01 | 2004-11-30 | Фармацевтические композиции |
Country Status (11)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1478648B1 (en) | 2002-02-01 | 2014-04-30 | ARIAD Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
| WO2006053754A1 (en) * | 2004-11-19 | 2006-05-26 | Novartis Ag | COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE |
| AU2006315512B2 (en) * | 2005-11-14 | 2012-11-01 | Ariad Pharmaceuticals, Inc. | Administration of an mTOR inhibitor to treat patients with cancer |
| EP1880723A1 (en) * | 2006-07-14 | 2008-01-23 | Novartis AG | Combination of mTOR inhibitor and antifolate compound |
| JP2009523149A (ja) * | 2006-01-12 | 2009-06-18 | ノバルティス アクチエンゲゼルシャフト | ｍＴＯＲ阻害剤および抗葉酸化合物の組み合わせ |
| KR20140016439A (ko) * | 2006-02-02 | 2014-02-07 | 노파르티스 아게 | 결절성 경화증의 치료 |
| US20090023768A1 (en) * | 2006-02-24 | 2009-01-22 | Novartis Ag | Rapamycin derivatives for treating neuroblastoma |
| CA2669415A1 (en) | 2006-11-14 | 2008-05-22 | Ariad Pharmaceuticals, Inc. | Solid dosage form comprising ap23573 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| DE69624921T2 (de) * | 1995-06-09 | 2003-09-11 | Novartis Ag, Basel | Rapamycinderivate |
| GB0123025D0 (en) * | 2001-09-25 | 2001-11-14 | Eirx Therapeutics Ltd | Apoptosis |
| JP2005514411A (ja) * | 2002-01-10 | 2005-05-19 | ノバルティス アクチエンゲゼルシャフト | ラパマイシンおよびその誘導体を含む血管疾患の予防および処置用薬剤送達システム |
| EP1478648B1 (en) * | 2002-02-01 | 2014-04-30 | ARIAD Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
| WO2003106622A2 (en) * | 2002-05-30 | 2003-12-24 | The Children's Hospital Of Philadelphia | Methods for treatment of acute lymphocytic leukemia |
| TW200902047A (en) * | 2003-02-14 | 2009-01-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
-
2003
- 2003-12-01 GB GBGB0327840.5A patent/GB0327840D0/en not_active Ceased
-
2004
- 2004-11-30 KR KR1020067010547A patent/KR20060122877A/ko not_active Withdrawn
- 2004-11-30 US US10/581,069 patent/US20070117833A1/en not_active Abandoned
- 2004-11-30 CN CNA2004800355130A patent/CN1886157A/zh active Pending
- 2004-11-30 JP JP2006541869A patent/JP2007512381A/ja active Pending
- 2004-11-30 RU RU2006123312/15A patent/RU2006123312A/ru not_active Application Discontinuation
- 2004-11-30 BR BRPI0417146-2A patent/BRPI0417146A/pt not_active IP Right Cessation
- 2004-11-30 AU AU2004294282A patent/AU2004294282B2/en not_active Expired - Fee Related
- 2004-11-30 WO PCT/EP2004/013587 patent/WO2005053661A2/en not_active Ceased
- 2004-11-30 CA CA002546738A patent/CA2546738A1/en not_active Abandoned
- 2004-11-30 EP EP04803369A patent/EP1819361A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| GB0327840D0 (en) | 2003-12-31 |
| AU2004294282B2 (en) | 2009-05-07 |
| BRPI0417146A (pt) | 2007-03-06 |
| CN1886157A (zh) | 2006-12-27 |
| EP1819361A2 (en) | 2007-08-22 |
| WO2005053661A3 (en) | 2005-12-29 |
| US20070117833A1 (en) | 2007-05-24 |
| JP2007512381A (ja) | 2007-05-17 |
| CA2546738A1 (en) | 2005-06-16 |
| AU2004294282A1 (en) | 2005-06-16 |
| WO2005053661A2 (en) | 2005-06-16 |
| KR20060122877A (ko) | 2006-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005063297A3 (en) | Melatonin combination therapy for improving sleep quality | |
| EP1426375A3 (en) | Analgesic spiroindole derivatives | |
| IL144636A (en) | Thioamide derivatives | |
| WO2002069904A3 (en) | Cd2 antagonists for treatment of autoimmune or inflammatory disease | |
| WO2003068171A3 (en) | Method and composition for treatment of inflammation and aids-associated neurological disorders | |
| WO2005047244A3 (en) | Inhibition of fgfr3 and treatment of multiple myeloma | |
| JP2005528431A (ja) | アルツハイマー病を治療するためのｎｍｄａ−アンタゴニスト及びアセチルコリンエステラーゼ阻害剤の組み合わせ物 | |
| CA2532565A1 (en) | Use of calcitonin in osteoarthritis | |
| EP1769797A3 (en) | Methods and compositions using cetirizine in combination with leukotriene inhibitors for treating conditions responsive to leukotriene inhibition | |
| WO2004039325A3 (en) | Treatment of pain with jnk inhibitors | |
| PL368971A1 (en) | Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | |
| CA2274686A1 (en) | Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds | |
| EP1086099A4 (en) | COMPOUNDS BASED ON SULFONIC ACID OR SULFONYLAMINO N- (HETEROARALKYL) -AZAHETEROCYCLYLAMIDE | |
| JP2023523706A5 (cg-RX-API-DMAC10.html) | ||
| CA2893768C (en) | Topical preparation for pain relief | |
| RU2007119067A (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи | |
| WO2002065989A3 (en) | Aminoglycoside treatment for lysosomal storage diseases | |
| CA2476939A1 (en) | Pharmaceutical combinations of cox-2 inhibitors and opiates | |
| IL145269A0 (en) | Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders | |
| WO2001005408A8 (en) | Fat-binding polymers, optionally combined with lipase inhibitors | |
| PT1244438E (pt) | Utilizacao de antagonistas dos receptores beta-adrenergicos para o fabrico de um medicamento destinado ao tratamento de perturbacoes da retina externa | |
| WO2025137652A3 (en) | Compositions comprising radiprodil and the use of radiprodil in the treatment of epileptic or neurobehavioral disorders | |
| JP2007512381A5 (cg-RX-API-DMAC10.html) | ||
| US5081129A (en) | Method of treatment of anemia with seratonin antagonists | |
| Funk et al. | Diclofenac patches for postoperative shoulder pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090629 |